SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News: Aerocrine AB (STO:AEROB) announces that it has become a partner in a program for the development of diagnostic methods for allergies, asthma and food hypersensitivity. The purpose of the research program is to develop simple diagnostic methods for allergies, asthma and food hypersensitivity for use in specialist and primary healthcare. The objective of the program is to develop and clinically assess equipment to measure inflammation in the peripheral airways by means of exhaled air, and equipment to ascertain the type and degree of intestinal inflammation by means of rectal gas and fluid samples. Efforts will also seek to enable the measurement of various types of antibodies and other inflammation indicators in blood, saliva and intestinal secretions. With its new product NIOX® Flex, Aerocrine also advances the possibility of determining which area of the airways is inflamed. This can be of great importance for selecting treatment in patients with asthma.
